Daratumumab
2017-0243
Phase 1 mab active
Quick answer
Daratumumab for Newly Diagnosed Primary Amyloidosis is a Phase 1 program (mab) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Newly Diagnosed Primary Amyloidosis
- Phase
- Phase 1
- Modality
- mab
- Status
- active